RU2412941C2 - Полиморфы натриевой соли n-(4-хлор-3-метил-5-изоксазолил)-2[2-метил-4,5-(метилендиокси)фенилацетил]тиофен-3-сульфонамида - Google Patents

Полиморфы натриевой соли n-(4-хлор-3-метил-5-изоксазолил)-2[2-метил-4,5-(метилендиокси)фенилацетил]тиофен-3-сульфонамида Download PDF

Info

Publication number
RU2412941C2
RU2412941C2 RU2008136316/04A RU2008136316A RU2412941C2 RU 2412941 C2 RU2412941 C2 RU 2412941C2 RU 2008136316/04 A RU2008136316/04 A RU 2008136316/04A RU 2008136316 A RU2008136316 A RU 2008136316A RU 2412941 C2 RU2412941 C2 RU 2412941C2
Authority
RU
Russia
Prior art keywords
methyl
polymorph
solvent
phenylacetyl
methylenedioxy
Prior art date
Application number
RU2008136316/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2008136316A (ru
Inventor
Джон Ф. РЕЙХВЕЙН (US)
Джон Ф. РЕЙХВЕЙН
Тим ХАНСЕН (US)
Тим ХАНСЕН
Original Assignee
Инсайсив Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инсайсив Фармасьютикалз, Инк. filed Critical Инсайсив Фармасьютикалз, Инк.
Publication of RU2008136316A publication Critical patent/RU2008136316A/ru
Application granted granted Critical
Publication of RU2412941C2 publication Critical patent/RU2412941C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2008136316/04A 2006-03-13 2007-03-12 Полиморфы натриевой соли n-(4-хлор-3-метил-5-изоксазолил)-2[2-метил-4,5-(метилендиокси)фенилацетил]тиофен-3-сульфонамида RU2412941C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78186106P 2006-03-13 2006-03-13
US60/781,861 2006-03-13

Publications (2)

Publication Number Publication Date
RU2008136316A RU2008136316A (ru) 2010-04-20
RU2412941C2 true RU2412941C2 (ru) 2011-02-27

Family

ID=38335653

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008136316/04A RU2412941C2 (ru) 2006-03-13 2007-03-12 Полиморфы натриевой соли n-(4-хлор-3-метил-5-изоксазолил)-2[2-метил-4,5-(метилендиокси)фенилацетил]тиофен-3-сульфонамида

Country Status (14)

Country Link
US (1) US20090104265A1 (enExample)
EP (1) EP1996582A2 (enExample)
JP (1) JP2009530279A (enExample)
KR (1) KR101019264B1 (enExample)
CN (1) CN101443329A (enExample)
AU (1) AU2007225206B2 (enExample)
BR (1) BRPI0709384A2 (enExample)
CA (1) CA2644134A1 (enExample)
IL (1) IL193682A0 (enExample)
MX (1) MX2008011843A (enExample)
NZ (1) NZ570943A (enExample)
RU (1) RU2412941C2 (enExample)
WO (1) WO2007106467A2 (enExample)
ZA (1) ZA200807302B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112241A1 (en) * 2007-03-13 2008-09-18 Encysive Pharmaceuticals, Inc. Methods an compositions for treatment of an interstitial lung disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
RU2005114487A (ru) * 2002-10-12 2006-02-10 Астразенека Аб (Se) Терапевтическое лечение
WO2006026395A1 (en) * 2004-08-26 2006-03-09 Encysive Pharmaceuticals Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5793705A (en) * 1996-09-18 1998-08-11 International Business Machines Corporation Ultrasonic liquid level gauge for tanks subject to movement and vibration
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP4097893B2 (ja) * 2000-12-05 2008-06-11 株式会社エフ・ティ・エスコーポレーション 対向ターゲット式スパッタ方法及び導電性膜の形成方法
ES2274234T3 (es) * 2002-03-15 2007-05-16 Novartis Ag 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3(4-piridin-3-il)pirimidin -2-ilamino)fenil)-benzamida para el tratamiento de enfermedades mediadas por ang ii.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
RU2005114487A (ru) * 2002-10-12 2006-02-10 Астразенека Аб (Se) Терапевтическое лечение
WO2006026395A1 (en) * 2004-08-26 2006-03-09 Encysive Pharmaceuticals Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof

Also Published As

Publication number Publication date
BRPI0709384A2 (pt) 2011-03-22
IL193682A0 (en) 2009-05-04
WO2007106467A3 (en) 2007-10-25
NZ570943A (en) 2010-09-30
MX2008011843A (es) 2008-10-02
CA2644134A1 (en) 2007-09-20
ZA200807302B (en) 2009-11-25
WO2007106467A2 (en) 2007-09-20
AU2007225206A1 (en) 2007-09-20
EP1996582A2 (en) 2008-12-03
KR101019264B1 (ko) 2011-03-07
KR20080106926A (ko) 2008-12-09
AU2007225206B2 (en) 2010-08-05
CN101443329A (zh) 2009-05-27
US20090104265A1 (en) 2009-04-23
RU2008136316A (ru) 2010-04-20
JP2009530279A (ja) 2009-08-27

Similar Documents

Publication Publication Date Title
JP5746185B2 (ja) 三置換１ｈ−ピロール類と、芳香族スペーサーおよびヘテロ芳香族スペーサーとに同時に基づく新規ヒストンデアセチラーゼ阻害剤
CN1561341A (zh) 用氢氧化钙水解[R(R*,R*)]－2－(4－氟代苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[（苯基氨基）羰基]－1H－吡咯－1－庚酸酯
JP6532607B2 (ja) スルホンアミド化合物又はその塩
CA2958625C (en) Crystal of pyrrole derivative and method for producing the same
JP2009530281A5 (enExample)
HRP20141178T1 (hr) Äśvrsti gama karbolin kondenziran sa supstituiranim heterociklusom
JP2010514832A5 (enExample)
CN102827153B (zh) 阿齐沙坦的晶型及其制备方法
RU2015103065A (ru) Кристаллическая форма i дималеата ингибитора тирозинкиназы и способ ее получения
JP2020517677A5 (enExample)
US20120289701A1 (en) Forms of lapatinib ditosylate and processes for preparation thereof
WO2015097605A1 (en) Process for the preparation of sofosbuvir
JP2013511475A5 (enExample)
Kumar et al. A facile synthesis of naturally occurring 5-(3-indolyl) oxazoles
RU2412941C2 (ru) Полиморфы натриевой соли n-(4-хлор-3-метил-5-изоксазолил)-2[2-метил-4,5-(метилендиокси)фенилацетил]тиофен-3-сульфонамида
Mathews et al. Synthesis of pyrimidine-5-carbaldehydes from α-formylaroylketene dithioacetals
RU2017102321A (ru) Новая поликристаллическая форма пролекарства тенофовира и способ ее получения и ее применение
JP2020517676A5 (enExample)
KR20120027321A (ko) 신규 옥사졸리디논 유도체
RU2007143025A (ru) Полиморфизм додекагидроклопента[а]фенантренилового эфира тиофенкарбоновой кислоты
RU2015122717A (ru) 2-пиридоновое соединение
HRP20161485T1 (hr) Polimorfna forma n-[4-(trifluorometil)benzil)-4-metoksibutiramida
CN111892544A (zh) 一种3-（氨基甲基）-4-（4-氟苯基）哌嗪-1-羧酸叔丁酯及其合成方法
CN102432490A (zh) 一种阿戈美拉汀晶型d及其制备方法
CN104788435A (zh) 一种蛋白酪氨酸激酶抑制剂的二苯磺酸盐的i型结晶

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120313